Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.
ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.
ACC 2018 Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.
ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.
ACC 2018 In a sub-analysis of the CANTOS trial, canakinumab showed a similar CV event reduction in diabetics and non-diabetics, but did not prevent the progression from pre-diabetes to diabetes.
ACC 2018 Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.
Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab
Prof. Stroes describes the 3 pathways involved in progression of atherosclerosis and new algorithms to reduce residual risk with personalized therapy.
Prof. Wolfgang Koenig explains the role of inflammation in the atherogenic process and how to identify patients with residual inflammatory risk.
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.
In a sub-analysis of the ARIC study, midlife systemic inflammation was associated with the development of chronic microangiopathic structural white matter abnormalities in the elderly.
AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but response to treatment did.
AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP < 2 mg/L benefitted from a reduction in MACE and mortality, irrespective of the dose of canakinumab.